Table 2 Expected success rates of high-flow nasal cannula therapy in the different indications
From: High-flow nasal cannula therapy: clinical practice in intensive care units
| Â | Overall, % (n) | Seniors, % (n) | Juniors, % (n) | p* |
|---|---|---|---|---|
All indications | Â | Â | Â | 0.95 |
 1–19% | 5 (5/104) | 5 (3/66) | 5 (2/38) |  |
 20–39% | 35 (36/104) | 30 (20/66) | 42 (16/38) |  |
 40–59% | 41 (43/104) | 44 (29/66) | 36 (14/38) |  |
 ≥ 60% | 19 (20/104) | 21 (14/66) | 16 (6/38) |  |
Hypoxemic ARF | Â | Â | Â | 0.81 |
 1–19% | 6 (7/120) | 5 (4/75) | 7 (3/45) |  |
 20–39% | 23 (28/120) | 19 (14/75) | 31 (14/45) |  |
 40–59% | 41 (49/120) | 45 (34/75) | 33 (15/45) |  |
 ≥ 60% | 30 (36/120) | 31 (23/75) | 29 (13/45) |  |
Hypercapnic ARF | Â | Â | Â | 0.88 |
 1–19% | 35 (16/46) | 33 (9/27) | 37 (7/19) |  |
 20–39% | 46 (21/46) | 44 (12/27) | 47 (9/19) |  |
 40–59% | 17 (8/46) | 22 (8/27) | 11 (2/19) |  |
 ≥ 60% | 2 (1/46) | 0 | 5 (1/19) |  |